ADAP

Adaptimmune Therapeutics Plc

ADAP.US adaptimmune.com + Research + Basket
CIK 0001621227
Employees 506
Phone 44 12 3543 0000
Fiscal year end December
IPO May 06, 2015
Address 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
Price N/A
USD · NASDAQ
52-week range
0.04
0.05
Market Cap
14.55M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-0.27
Div. Yield
N/A
% Institutions
31.23%
% Insiders
0.631%

1 Year

-95.7%

3 Year

-97.8%

10 Year

-99.7%
Description

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Actions

Add an action for ADAP.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Adrian G. Rawcliffe CEO & Director 1972
Mr. William Charles A. Bertrand Jr., Esq., J.D. COO, Chief Compliance Officer & Secretary 1965
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. Co-Founder 1967
Mr. Christopher James Hill ACA, BA (Hons) Chief Financial Officer 1980
Dr. Juli P. Miller Ph.D. VP of Corporate Affairs & Investor Relations NA
Ms. Kerry Sharp Senior VP & General Counsel NA
Ms. Dana Lynch Senior Director of Corporate Communications NA
Ms. Kimberly Freeman Vice President of Commercial Planning NA
Laura Gunn Vice President of Medical Affairs NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Sep 02, 2025 Gavin Wood N/A Sale 96.00K $0.01 $960.00 SEC
Aug 28, 2025 William C Bertrand Jr N/A Sale 207.00K $0.01 $2.07K SEC
Aug 18, 2025 Ali Behbahani N/A Sale 14.67M $0.01 $146.72K SEC
Aug 15, 2025 Ali Behbahani N/A Sale 4.83M $0.01 $48.28K SEC
Jan 17, 2025 Elliot Norry N/A Sale 5.58K $0.58 $3.24K SEC
Jan 15, 2025 Cintia Piccina N/A Sale 12.99K $0.57 $7.40K SEC
Jan 15, 2025 William C Bertrand Jr N/A Sale 9.80K $0.57 $5.59K SEC
Jan 13, 2025 Elliot Norry N/A Sale 12.39K $0.59 $7.31K SEC
Jan 13, 2025 William C Bertrand Jr N/A Sale 9.74K $0.59 $5.75K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
EcoR1 Capital, LLC 27.40M Jun 30, 2025 10.34% $0.39 0.00%
Long Focus Capital Management, LLC 23.76M Jun 30, 2025 8.96% $0.22 0.00%
Two Seas Capital LP 22.58M Jun 30, 2025 8.52% $0.09 9.99%
NEA Management Company, LLC 17.08M Jun 30, 2025 6.44% $0.31 0.00%
Mpm Asset Management, LLC 4.81M Jun 30, 2025 1.81% $2.66 -9.86%
MPM Oncology Impact Management LP 4.41M Jun 30, 2025 1.66% $0.18 -9.86%
Morgan Stanley - Brokerage Accounts 4.23M Jun 30, 2025 1.60% $0.00 55.83%
Rock Springs Capital Management LP 2.48M Jun 30, 2025 0.94% $0.04 0.00%
Renaissance Technologies Corp 1.88M Jun 30, 2025 0.71% $0.00 3.80%
Bank of America Corp 1.14M Jun 30, 2025 0.43% $0.00 -0.46%
Empirical Finance, LLC 800.00K Jun 30, 2025 0.30% $0.01 0.00%
FMR Inc 464.28K Jun 30, 2025 0.18% $0.00 -73.54%
Rathbone Brothers PLC 432.82K Jun 30, 2025 0.16% $0.00 0.00%
State Street Corp 426.71K Jun 30, 2025 0.16% $0.00 1.29%
BlackRock Inc 179.09K Jun 30, 2025 0.07% $0.00 -2.50%
Key Client Fiduciary Advisors, LLC 175.56K Jun 30, 2025 0.07% $0.02 16.92%
Clear Harbor Asset Management, LLC 145.40K Jun 30, 2025 0.05% $0.00 -39.60%
Almitas Capital LLC 109.05K Jun 30, 2025 0.04% $0.01 0.00%
Advisor Group Holdings, Inc. 90.06K Jun 30, 2025 0.03% $0.00 38.43%
XTX Topco Ltd 80.02K Jun 30, 2025 0.03% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Galileo - Biotech Innovation Fund S USD 752.46K 0.28% ▲ 0.00% Feb 28, 2025
2 SPDR® Portfolio Developed Wld ex-US ETF 296.36K 0.11% ▲ 0.00% Aug 29, 2025
3 SPDR® S&P® International Small Cap ETF 143.92K 0.05% ▲ 0.00% Aug 29, 2025
4 Fidelity Nasdaq Composite Index 67.03K 0.03% ▲ 0.00% Jul 31, 2025
5 Club Innovation Santé 45.35K 0.02% ▲ 0.00% Aug 31, 2025
6 Northern Small Cap Core I 16.89K 0.01% ▲ 0.00% Jun 30, 2025
7 NT Quality Small Cap Core 9.55K 0.00% ▲ 0.00% Jun 30, 2025
8 NT Quality SCC US Fund - L 9.55K 0.00% ▲ 0.00% Jun 30, 2025
9 Guggenheim Active Allocation Fund 273.00 0.00% ▲ 0.00% May 31, 2025

Financial Highlights

▼
Market Cap: $14.55M
EBITDA: $-137.24M
PEG Ratio: $0.11
Book Value: $-0.27
Earnings/Share: $-0.66
Profit Margin: -260.82%
Operating Margin: -221.45%
ROA (TTM): -40.86%
ROE (TTM): -1,341.10%
Revenue (TTM): $65.09M
Revenue/Share (TTM): $0.25
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -89.30%

Valuation Metrics

Enterprise Value: $31.98M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 265.05M
Shares Float: 1.22B
% Insiders: 0.631%
% Institutions: 31.23%
Shares Short: 31.38M
Shares Short (Prior Month): 29.65M
Short Ratio: 0.19
Short % Float: 14.34%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$178.03M
Cost of Goods Sold
adjust
$-70.00K
Gross Profit
subtotal
$177.96M
SG&A
adjust
$-80.81M
R&D
adjust
$-149.06M
Other Operating Expense
adjust
$-16.86M
Operating Income
subtotal
$-68.76M
Other / Non-Operating Items
adjust
$-2.05M
Net Income
subtotal
$-70.81M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ADAP.US!